Menu Search
Equities

BCAL Diagnostics Ltd

BDX:ASX

BCAL Diagnostics Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.11
  • Today's Change0.005 / 4.76%
  • Shares traded300.00k
  • 1 Year change+10.00%
  • Beta0.5901
Data delayed at least 20 minutes, as of Nov 17 2024 23:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year BCAL Diagnostics Ltd had net income fall 26.44% from a loss of 5.06m to a larger loss of 6.40m despite a 9.18% increase in revenues from 2.79m to 3.05m. An increase in the selling, general and administrative costs as a percentage of sales from 117.18% to 142.19% was a component in the falling net income despite rising revenues.
Gross margin--
Net profit margin-210.07%
Operating margin-208.48%
Return on assets-62.03%
Return on equity-92.74%
Return on investment-81.11%
More ▼

Cash flow in AUDView more

In 2024, BCAL Diagnostics Ltd increased its cash reserves by 103.93%, or 3.30m. Cash Flow from Financing totalled 8.97m or 294.51% of revenues. In addition the company used 4.52m for operations while cash used for investing totalled 1.15m.
Cash flow per share-0.0236
Price/Cash flow per share--
Book value per share0.0273
Tangible book value per share0.0273
More ▼

Balance sheet in AUDView more

BCAL Diagnostics Ltd appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 6.47m.
Current ratio3.60
Quick ratio--
Total debt/total equity0.1774
Total debt/total capital0.1507
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.